REDX PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15 GBX | +31.58% |
|
-.--% | -31.82% |
Presenter SpeechRachel Gravesen (Attendees)Hello, and welcome. Thanks very much for joining us...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. The Companyâs pipeline includes zelasudil (RXC007), zamaporvint (RXC004) and RXC008. Its lead asset, zelasudil (RXC007), a selective ROCK2 inhibitor, with potential in multiple interstitial lung diseases and cancer-associated fibrosis, is in a Phase 2 clinical program with an initial indication in idiopathic pulmonary fibrosis. RXC008 is a potential GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohnâs disease. Its oncology pipeline is led by zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy, and its drug discovery engine is advancing a pipeline of research programs and collaborations in both fibrotic diseases and oncology.
Calendar
2024-06-09
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.82% | 69.81M | |
| +3.18% | 108B | |
| +10.32% | 105B | |
| +1.57% | 23.46B | |
| -13.05% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.89% | 17.19B | |
| +5.78% | 13.99B | |
| +36.43% | 12.53B |
